Home › T-Cell Lymphoma › Connecticut › New Haven
T-Cell Lymphoma clinical trials in New Haven, CT
6 studies for T-Cell Lymphoma are looking for participants at sites in and around New Haven (within about 30 miles). Open a study to see who can join and how to contact the study team.
Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma
RecruitingPhase 3
- Yale University, New Haven
A Phase 2 Study of PTX 100 in Patients With Relapsed/Refractory CTCL
RecruitingPhase 2
- Yale Cancer Center, New Haven
Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory T-cell Lymphoma
RecruitingPhase 2
- Yale Smilow Cancer Hospital, New Haven
A Registry for People With T-cell Lymphoma
RecruitingObservational study
- Yale University (Data Collection Only), New Haven
Study of Mogamulizumab With DA-EPOCH or CHOEP in Patients With Aggressive T-cell Lymphoma
RecruitingPhase 2
- Yale Cancer Center, Clinical Trials Office, New Haven
Study of ONO-4685 in Patients With Relapsed or Refractory T Cell Lymphoma
RecruitingPhase 1
- Yale Cancer Center, New Haven
T-Cell Lymphoma trials in other cities
- New York City, NY14 studies
- Philadelphia, PA11 studies
- Boston, MA10 studies
- Baldwin Park, CA10 studies
- Houston, TX9 studies
- Atlanta, GA8 studies
- Rochester, MN6 studies
- Chicago, IL6 studies
- Columbus, OH6 studies
- Seattle, WA6 studies
- Miami, FL5 studies
- Portland, OR5 studies
Other studies in New Haven
- Non-Small Cell Lung Cancer41 studies
- Breast Cancer37 studies
- Cancer (all types)34 studies
- Lung Cancer23 studies
- Metastatic Cancer23 studies
- Head and Neck Squamous Cell Carcinoma22 studies
- Prostate Cancer21 studies
- Colorectal Cancer21 studies
- Ovarian Cancer21 studies
- Acute Myeloid Leukemia19 studies
- Alcohol Use Disorder (AUD)17 studies
- Opioid Overdose17 studies
From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.